anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
Gray leaf spot (GLS) caused by Cercospora zeina or C. zeae-maydis is a major maize disease throughout the world. Although more than 100 QTLs resistant against GLS have been identified, very few of them have been cloned. Here, we identified a major resistance QTL against GLS, qRglsSB, explaining 58.42% phenotypic variation in SB12×SA101 BC1 F1 population. By fine-mapping, it was narrowed down into a 928 kb region. By using transgenic lines, mutants and complementation lines, it was confirmed that the ZmWAK02 gene, encoding an RD wall-associated kinase, is the responsible gene in qRglsSB resistant against GLS. The introgression of the ZmWAK02 gene into hybrid lines significantly improves their grain yield in the presence of GLS pressure and does not reduce their grain yield in the absence of GLS. In summary, we cloned a gene, ZmWAK02, conferring large effect of GLS resistance and confirmed its great value in maize breeding.
Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
Pacerone® (Amiodarone HCl) Tablets are intended for use only in patients with the indicated life-threatening arrhythmias because amiodarone use is accompanied by substantial toxicity.

Amiodarone has several potentially fatal toxicities, the most important of which is pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 10 to 17% in some series of patients with ventricular arrhythmias given doses around 400 mg/day, and as abnormal diffusion capacity without symptoms in a much higher percentage of patients. Pulmonary toxicity has been fatal about 10% of the time. Liver injury is common with amiodarone, but is usually mild and evidenced only by abnormal liver enzymes. Overt liver disease can occur, however, and has been fatal in a few cases. Like other antiarrhythmics, amiodarone can exacerbate the arrhythmia, e.g., by making the arrhythmia less well tolerated or more difficult to reverse. This has occurred in 2 to 5% of patients in various series, and significant heart block or sinus bradycardia has been seen in 2 to 5%. All of these events should be manageable in the proper clinical setting in most cases. Although the frequency of such proarrhythmic events does not appear greater with amiodarone than with many other agents used in this population, the effects are prolonged when they occur.

Even in patients at high risk of arrhythmic death, in whom the toxicity of amiodarone is an acceptable risk, Pacerone® Tablets pose major management problems that could be life-threatening in a population at risk of sudden death, so that every effort should be made to utilize alternative agents first.

The difficulty of using Pacerone® Tablets effectively and safely itself poses a significant risk to patients. Patients with the indicated arrhythmias must be hospitalized while the loading dose of Pacerone® Tablets is given, and a response generally requires at least one week, usually two or more. Because absorption and elimination are variable, maintenance-dose selection is difficult, and it is not unusual to require dosage decrease or discontinuation of treatment. In a retrospective survey of 192 patients with ventricular tachyarrhythmias, 84 required dose reduction and 18 required at least temporary discontinuation because of adverse effects, and several series have reported 15 to 20% overall frequencies of discontinuation due to adverse reactions. The time at which a previously controlled life-threatening arrhythmia will recur after discontinuation or dose adjustment is unpredictable, ranging from weeks to months. The patient is obviously at great risk during this time and may need prolonged hospitalization. Attempts to substitute other antiarrhythmic agents when Pacerone®  Tablets must be stopped will be made difficult by the gradually, but unpredictably, changing amiodarone body burden. A similar problem exists when amiodarone is not effective; it still poses the risk of an interaction with whatever subsequent treatment is tried.
PURPOSE:To obtain the new compound consisting of 3,4-(6-carboxymethano) proline, having suppressing action against L-glutamic acid transporter's intake activity on a glutamic acid of a neurotransmitter and useful for the treatment of a neuron degenerative disease. CONSTITUTION:This is a new compound of a 3,4-(6-carboxymethano)proline [e.g. (2S,3S,4S,6R)-3,4-(6-carboxymethano)prolinel which has a suppressive action against the intake activity of a neurotransmitter, i.e., an L-glutamic acid expressed by formula I, useful for the elucidation of the function of a glutamic acid transporter and expected to develop in the field of e.g. treatment of a neuron degenerative disease, e.g. epilepsy, Huntington's chorea and Parkinson's disease. This compound is obtained by opening the oxazolidine ring of a compound of formula II (TBS is t-butyldimethylsilyl), protecting the hydroxyl and amino groups, then reducing the product to obtain a compound of formula III (Boc is t-butoxycarbonyl), removing protecting groups (TBS), subjecting the product to Jones oxidation and then methyl esterification, hydrolyzing and finally removing the protecting group (Boc) successively.
Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m\^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m\^2/day for 7 days in 1 28 day cycle), then 200 mg/m\^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m\^2/day for 21 days of each 28-day cycle (12 cycle maximum).
Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
The present invention relates to a composition comprising an extract of Malvaviscus arboreus var. penduliflorus (DC.) Schery having an anti-inflammatory activity, and more specifically, to an anti-inflammatory cosmetic composition, an anti-inflammatory pharmaceutical composition, and an anti-inflammatory food composition, comprising an extract of Malvaviscus arboreus var. penduliflorus (DC.) Schery. Since the extract of Malvaviscus arboreus var. penduliflorus (DC.) Schery of the present invention suppresses the production and secretion of inflammatory mediators such as NO and TNF-α, the compositions using the same as a raw material can effectively reduce inflammation, and thus the anti-inflammatory compositions comprising the same as an effective component may be applied as an anti-inflammatory agent for suppressing inflammation in inflammation-related diseases, a pharmaceutical composition having an anti-inflammation effect, a cosmetic composition, a health food composition, etc.
The invention provides an article of manufacture comprising a substantially non-immunogenic heart valve xenograft for implantation into humans. The invention further provides methods for preparing a heart valve xenograft by removing at least a portion of a soft tissue from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to cellular disruption treatment; treating the xenograft with crosslinking agents, and digesting the xenograft with a proteoglycan-depleting factor and/or glycosidase. The invention also provides an article of manufacture produced by the above-identified method of the invention. The invention further provides a heart valve xenograft for implantation into a human including a portion of a heart valve from a non-human animal, wherein the portion has extracellular components and substantially only dead cells. The extracellular components have reduced proteoglycan molecules. Each of the xenografts of the invention is substantially non-immunogenic and has substantially the same mechanical properties as a corresponding native heart valve.
NEW MATERIAL:The compound of formula [either one of R1 and R2 is H and the other is RZQ (R is bonding group composed of 1-10C atoms and hetero atoms consisting of straight-chain or branched chain containing <=10 hetero atoms, provided that more than two hetero atoms are not bonded adjacent to each other; Z is C=O, SO2, etc.; Q is H, halogen, etc.)]. EXAMPLE:N<1>-(carbo-t-butoxymethyl)clonazepam. USE:A clonazepam(CZP) immunogen substance useful for the immunological determination of CZP in body fluid such as urine and serum for performing an effective therapeutic treatment with CZP known as an antiepileptic agent, etc. PREPARATION:The exemplified compound can be produced e.g. by adding a methanol solution of sodium methoxide to an anhydrous DMF solution of CZP, stirring the mixture for 10min at room temperature, adding t-butyl- bromoacetate and reacting the components under stirring for a whole day and night.
PROBLEM TO BE SOLVED: To provide a new compound useful as an antibacterial and fungicidal agent. SOLUTION: This compound is expressed by the formula I (X is a halogen; R is a 1-20C alkyl; (n) is 0 or 1), e.g. 2,5-bis(N,N-dimethyl-N-octylammoniomethyl) thiophene chloride. The compound of the formula I can be produced by reacting a halogenated methylthiophene derivative of the formula II with a dimethylmonoalkylamine of the formula, N(CH3 )2 R (R is a 1-20C alkyl). The halogenated methylthiophene derivative of the formula II is producible e.g. from thiophene existing in a petroleum fraction by reacting with a compound of the formula, HX.
Lung fibrosis is a complex process, with unknown underlying mechanisms, involving various triggers, diseases and stimuli. Different cell types (epithelial cells, endothelial cells, fibroblasts and macrophages) interact dynamically through multiple signalling pathways, including biochemical/molecular and mechanical signals, such as stiffness, affecting cell function and differentiation. Idiopathic pulmonary fibrosis (IPF) is the most common fibrosing interstitial lung disease (fILD), characterised by a notably high mortality. Unfortunately, effective treatments for advanced fILD, and especially IPF and non-IPF progressive fibrosing phenotype ILD, are still lacking. The development of pharmacological therapies faces challenges due to limited knowledge of fibrosis pathogenesis and the absence of pre-clinical models accurately representing the complex features of the disease. To address these challenges, new model systems have been developed to enhance the translatability of preclinical drug testing and bridge the gap to human clinical trials. The use of two- and three-dimensional in vitro cultures derived from healthy or diseased individuals allows for a better understanding of the underlying mechanisms responsible for lung fibrosis. Additionally, microfluidics systems, which replicate the respiratory system's physiology ex vivo, offer promising opportunities for the development of effective therapies, especially for IPF.
Systems and methods for generating neuroprotective and cardioprotective nutrition programs are described herein. These neuroprotective and cardioprotective nutrition programs are especially applicable for patients at risk of cardiac arrest (e.g. due to hypoxia or ischemia of the brain or other body parts). The programs may feature caloric restriction, for example, short-term caloric restriction. The programs may be generated or iteratively modified based on the hemodynamic and metabolic state of the patient's brain, limbs, or other tissues or organs. Dynamic feedback about the patient's hemodynamic and metabolic state may be provided by techniques including, but not limited to, optical technology for quantitatively and noninvasively measuring blood flow, oxygenation, metabolic rate of oxygen, and perfusion/metabolism ratio in the brain, limbs, or other tissues or organs. The systems described herein may also induce spreading depolarization and repolarization at specific times during or after cardiac arrest based on the patient's cerebral metabolic state.
PURPOSE: To obtain a high-quality and low-residue solid preparation useful as a medicine for esp. inflammatory enteropathy with its lesions inside the digestive tracts, by fluidized bed granulation of a composition containing active ingredients and a dextrin. CONSTITUTION: A solution containing a dextrin as binder and, a 5-aminosalicylic acid compound and balsalazide compound as active ingredients, is sprayed with e.g. a spray gun and dried simultaneously into granules (fluidized bed granulation method). The granulated product is dried and sieved into the objective solid preparation. The weight ratio of the active ingredients to the dextrin is (95:5) to (70:30). In manufacturing a preparation of such a medicine for patients with lesions inside the digestive tracts, who need to suppress the use of an additive nonabsorbable to the digestive tracts to a minimum, the dextrin is only a usable additive among a number of additives because it is low in irritancy and antigen nature and has such characteristics as to be hard to left residues owing to its absorption inside the digestive tracts.
PURPOSE: This report aims to present a case of corneal keloid caused by chronic corneal insult after trauma and Descemet stripping automated endothelial keratoplasty (DSAEK).
CASE PRESENTATION: A 35-year-old male with a history of vision loss in the right eye was referred to our hospital. The patient underwent Ahmed Glaucoma Valve Implantation to alleviate elevated intraocular pressure after ocular trauma to the same eye. One year following the procedure, the eye developed endothelial failure, leading to the performance of Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) with repositioning of the shunt tube. Upon initial examination, a well-circumscribed elevated white opaque lesion involving the central corneal surface of the RE was observed. Based on the patient's clinical history, slit lamp examination, and UBM findings, the diagnosis of corneal keloid was established. Superficial keratectomy was performed. Histopathological analysis confirmed the diagnosis of corneal keloid. Following the procedure, BCVA improved slightly. However, 3 months later, the patient underwent a penetrating keratoplasty for visual rehabilitation.
CONCLUSION: Corneal keloids should be considered following any form of ocular trauma, particularly in cases involving ocular surgery. Diagnosing corneal keloids can sometimes be challenging due to the variety of potential differentials; however, by carefully evaluating the patient's medical history and clinical presentation, we can effectively narrow down the differential diagnosis of corneal conditions.
This phase II trial is a single-arm and single-center clinical study. Neoadjuvant chemotherapy is a standard treatment for locally advanced gastric cancer. The SOX regimen has became the standard perioperative chemotherapy regimen for locally advanced gastric cancer. For HER2-positive locally advanced gastric cancer, the neoadjuvant treatment is still based on chemotherapy alone. Some phase II studies have shown that chemotherapy combined with trastuzumab can further improve the pathological response. But it has not yet become a standard treatment strategy.

In the field of gastric cancer, checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer. PD-1 monoclonal antibody (Sintilimab) + trastuzumab + chemotherapy (SOX regimen ) may be an ideal perioperative treatment for HER2-positive locally advanced gastric cancer.
Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
No patients above the age of 65 years were enrolled in double-blind prospective clinical trials of mania associated with bipolar illness. In a case review study of 583 patients, 72 patients (12%) were greater than 65 years of age. A higher percentage of patients above 65 years of age reported accidental injury, infection, pain, somnolence, and tremor. Discontinuation of valproate was occasionally associated with the latter two events. It is not clear whether these events indicate additional risk or whether they result from preexisting medical illness and concomitant medication use among these patients.

A study of elderly patients with dementia revealed drug related somnolence and discontinuation for somnolence [see Warnings and Precautions (5.14)] . The starting dose should be reduced in these patients, and dosage reductions or discontinuation should be considered in patients with excessive somnolence [see Dosage and Administration (2.4)] . 

There is insufficient information available to discern the safety and effectiveness of valproate for the prophylaxis of migraines in patients over 65.
PURPOSE:To obtain a pharmaceutical, forming a fine emulsion and capable of being parenterally, especially intraveously administered, by kneading a sparingly soluble drug with an oily ingredient in the coexistence of a phospholipid, adding an aqueous solution and emulsifying the resultant kneaded blend. CONSTITUTION:A sparingly soluble drug hardly soluble in water and oils is sufficiently kneaded and blended with an adequate amount of an oily ingredient (preferably an oil, derived from a plant and purified to a high purity) and a phospholipid to form a homogeneous dispersion system, which is then mixed with a solution prepared by dissolving the residual phospholipid in the residual oily ingredient while heating and homogenized using a homomixer. An aqueous solution containing required additives, such as emulsification adjuvant, isotonizing agent, antioxidant, dissolved therein is then added to emulsify the obtained blend and afford the aimed emulsion pharmaceutical. The above- mentioned pharmaceutical preferably consists of 0.001-30wt./vol.% sparingly soluble drug, 1-30wt./vol.%, especially 5-20wt./vol.% oily ingredient, the phospholipid in an amount of 1-50pts.wt., especially 5-35pts.wt. based on 100pts.wt. oily ingredient and water in an adequate amount.
PROBLEM TO BE SOLVED: To obtain the subject composition exhibiting a sufficiently effective antioxidant strength to an oil phase component in an oil in water type emulsion, also handling easily, and safe to skin by blending a water soluble antioxidant and a specific oil soluble surfactant. SOLUTION: This antioxidant composition contains (A) a water soluble antioxidant (preferably a water soluble extract of a plant such as a peony) and (B) an oil soluble surfactant having <=8 HLB, preferably <=5 HLB (preferably, a polyglycerol fatty acid ester and lecithins). A weight ratio of the components A/B is set at (10/50)-(1/50). In order to aim at the uniformity of the objective composition, a hydrophilic medium can be contained. As the hydrophilic medium, glycerol, sorbitol, etc., are preferable. Further, in the case of using the water soluble plant extract as the component (A), it is preferable to perform the extraction by using water and/or ethanol, since there is no fear of showing a toxicity even if the solvent remain is in the O/W type emulsion preparation.
Approximately 30 subjects will be enrolled. The study includes a 19-day treatment period and a minimum 7-day washout period in which no test product is administered. Subjects will then crossover to a second 19-day treatment period to complete the study. Subjects receive test product (polyherbal capsule or placebo capsule) daily during the treatment periods. Two exercise test sessions followed up to 5 days will occur during the study using a modified seated arm-curl bench. Muscle strength is assessed on each day of the 5-day exercise test period. Safety is assessed during the study by collecting adverse events (AEs), clinical laboratory data (serum hematology and chemistry), and vital signs (blood pressure, pulse, respiration rate, temperature).
Percutaneous coronary intervention (PCI) with drug-eluting stents in left main (LM) disease has demonstrated similar results than surgical revascularization in patients with SYNTAX score \< 33, being the main drawback of PCI a higher rate of new revascularization. A small study found a reduction in the composite end-point of cardiac death, myocardial infarction and urgent revascularization with a routine angiographic follow-up. The investigators have designed a prospective, randomized, controlled, two-arm multicenter study in patients aged 18-85 with LM disease and SYNTAX score \<33 and in cases ≥ 33 based on the Heart Team decision to assess the benefit of a routine angiographic follow-up 6 months after LM stenting. After the index procedure and before hospital discharge the patient will be randomized to routine invasive angiographic follow-up at 6 months plus clinical follow-up at 6 months, 1, 2 and 3 years vs. the control arm, which would be followed clinically at 6 months, 1, 2 and 3 years. Based on our calculations, an adequately powered trial would require 1009 patients per arm but due to the uncertainty of the results and the current economical restrictions we have designed a pilot study in 400 patients to find out the convenience of an adequately powered trial. All the lesions should be treated with an everolimus eluting stent with permanent fluoropolymer. It will be desirable to achieve complete revascularization and it will be highly recommended to perform the procedures guided with an intravascular image technique (OCT or IVUS (IntraVascular UltraSound) according to operator´s criteria). The main outcome will be death, myocardial infarction and cerebrovascular accident at 3 years. The initial percutaneous technique and the decision about the convenience and way of revascularization in case of restenosis in the follow-up will be left at the operator´s discretion, according in the most adequate way to the current guidelines. Nonetheless, the investigators are strongly encouraged to rely on intravascular techniques, based on either imaging or physiology. In those cases with in-stent hyperplasia with doubts about possible restenosis, FFR and RFR (Resting full-cycle ratio) will be performed, with low threshold to achieve a high rate of ruling out the restenosis.